Sangamo Therapeutics Inc (SGMO) Receives $18.80 Consensus PT from Analysts

Sangamo Therapeutics Inc (NASDAQ:SGMO) has earned a consensus rating of “Hold” from the ten research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $18.80.

SGMO has been the topic of several research analyst reports. BidaskClub upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. ValuEngine downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 10th. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a report on Monday, November 19th. JPMorgan Chase & Co. downgraded shares of Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. Finally, Guggenheim downgraded shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a report on Friday, November 9th.

Sangamo Therapeutics stock traded up $0.19 during midday trading on Friday, hitting $8.99. 69,452 shares of the stock were exchanged, compared to its average volume of 2,454,387. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.32 and a quick ratio of 6.32. The firm has a market capitalization of $904.54 million, a price-to-earnings ratio of -12.86 and a beta of 2.84. Sangamo Therapeutics has a 52 week low of $6.26 and a 52 week high of $27.50.

In other news, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Monday, December 17th. The shares were sold at an average price of $11.44, for a total value of $57,200.00. Following the sale, the chief financial officer now directly owns 12,250 shares in the company, valued at $140,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 20,000 shares of company stock worth $231,500 over the last quarter. 1.20% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of SGMO. Bank of America Corp DE increased its holdings in Sangamo Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 159,812 shares of the biopharmaceutical company’s stock worth $1,834,000 after buying an additional 46,981 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Sangamo Therapeutics by 97.4% during the fourth quarter. Two Sigma Advisers LP now owns 203,300 shares of the biopharmaceutical company’s stock worth $2,334,000 after buying an additional 100,300 shares during the last quarter. Sphera Funds Management LTD. acquired a new position in Sangamo Therapeutics during the fourth quarter worth $3,903,000. Geode Capital Management LLC increased its holdings in Sangamo Therapeutics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 1,129,365 shares of the biopharmaceutical company’s stock worth $12,965,000 after buying an additional 15,750 shares during the last quarter. Finally, Tekla Capital Management LLC increased its holdings in Sangamo Therapeutics by 40.5% during the fourth quarter. Tekla Capital Management LLC now owns 241,538 shares of the biopharmaceutical company’s stock worth $2,773,000 after buying an additional 69,649 shares during the last quarter. Institutional investors own 62.27% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Recommended Story: What is Cost of Capital?

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit